highly significantP=0.0001
Furthermore, a highly significant increase in serum sTLR2 was detected in metastatic breast cancer patients (5,997.4±8,585.23) compared with non-metastatic patients (2,258.2±1,832.44; P=0.0001; Table III ) ( Fig. 1 ).
Furthermore, a highly significant increase in serum sTLR2 was detected in metastatic breast cancer patients (5,997.4±8,585.23) compared with non-metastatic patients (2,258.2±1,832.44; P=0.0001; Table III ) ( Fig. 1 ).